6533b7defe1ef96bd1276c00

RESEARCH PRODUCT

Discontinuation of treatment with Natalizumab after 24 courses. Report from spontaneous, observational, prospective study (TYSTOP).

M ClericoS De MercantiF PiazzaE VersinoD GnedM GibbinV Brescia MorraR LanzilloL AmatoM QuarantelliA GhezziA BianchiD BaronciniMt FerròF VitettaM D’onghiaD PaolicelliM TrojanoDurelli L.Giuseppe SalemiSabrina Realmuto

subject

Multiple Sclerosis Natalizumab TySTOPSettore MED/26 - Neurologiahttp://hdl.handle.net/10447/100464